MGMT and glioblastoma: Methylation of the O6–methylguanine DNA methyltransferase promoter (MGMT) is known to act as a strong drug-resistance-associated factor in GBM, and patients with isocitrate dehydrogenase (IDH) wildtype exhibit poor prognosis with standard treatment [8,9,10].